

Clinical trials of insulin secretagogues - Meglitinides (glinides) for diabetes type 2 in all types of patients

TrialResults-center www.trialresultscenter.org

1 meglitinides (glinides)

Trial	Treatments	Patients	Trials design and methods
repaglinide vs ???			
YSRE0001 [NCT00336310] n=NA follow-up: 12 weeks	Repaglinide versus NA	-	double-blind Taiwan
repaglinide vs control (add on MET)			
Moses , 1999 n=27/27 follow-up: 12 weeks	prestudy dose of metformin with the addition of repaglinide versus prestudy dose of metformin	patients with type 2 diabetes who had inadequate glycemic control (HbA1c >7.1%) when receiving the antidiabetic agent metformin	Parallel groups open
repaglinide vs glibenclamide			
Landgraf , 1999 n=NA follow-up: 14 weeks	repaglinide, administered preprandially three times daily versus glibenclamide, given preprandially once or twice daily	-	double-blind
Marbury , 1999 n=NA	-	-	
Wolffenbittel , 1999 n=211/109 follow-up: 1 year	repaglinide (0.5-4 mg t.i.d.) versus glyburide (1.75-10.5 mg daily)	-	double-blind
nateglinide vs glibenclamide (add on MET)			
Derosa , 2009 n=124/124 follow-up: 12 months	nateglinide versus glibenclamide	nave type 2 diabetic patients treated with metformin	double-blind
repaglinide vs gliclazide			
AGEE-3783 [NCT01022762] n=NA follow-up:	repaglinide (1 mg repaglinide twice daily (weeks 0-4), titrated versus gliclazide (80 mg gliclazide once daily (weeks 0-4), titrated	Chinese subjects with type 2 diabetes who never have been treated with oral anti-diabetic drugs	China
repaglinide vs glipizide			
Madsbad , 2001 n=256 follow-up: 1 year	repaglinide, 1-4 mg at mealtimes versus glipizide, 5-15 mg daily	-	double-blind

continued...

Trial	Treatments	Patients	Trials design and methods
nateglinide vs glyburide (add on MET)			
PRESERVE-beta n=NA follow-up:	-	-	
repaglinide + insulin vs insulin			
AGEE-1524 [NCT00799448] n=NA follow-up:	repaglinide combined with insulin NPH versus biphasic human insulin 30 alone	type 2 diabetics inadequately controlled with sulfonylurea (SU) +/- biguanide therapy	open Greece
AGEE-3020 n=NA	-	-	
mitiglinide+voglibose vs insulin glargine			
GLORIA [NCT00663884] n=NA follow-up: 16 weeks	combination therapy of 10 mg mitiglinide or 0.2mg voglibose versus insulin glargine	diabetic patients whose glycemic control were not enough despite administration of oral antidiabetic drug or insulin glargine	open Korea
nateglinide + metformin vs metformin			
Horton DOUBLON , 2000 n=172/178 follow-up: 24 weeks	nateglinide (120 mg, ac) and metformin (500 mg, tid) versus 500 mg metformin three times a day	-	
repaglinide vs metformin			
ReMet [NCT00118950] n=NA follow-up:	Repaglinide versus Metformin	Non-Obese Type 2 Diabetic Patients Uncontrolled by Diet	double-blind Denmark
Lund , 2007 n=NA follow-up:	repaglinide 2 mg thrice daily versus metformin 1 g twice daily	non-obese patients with type 2 diabetes	Cross over double-blind
repaglinide + metformin vs metformin			
AGEE-1411 [NCT01465152] n=NA follow-up:	-	-	open Spain
repaglinide vs Metformin (add on insulin)			
Reform [NCT00118963] n=NA follow-up:	Repaglinide + BIAsp30 versus Metformin + BIAsp30	non-obese patients with type-2-diabetes, uncontrolled on diet alone	double-blind
mitiglinide vs nateglinide			
Gao [NCT00461617] n=291 follow-up: 20 weeks	mitiglinide 10 - 20 mg three times daily versus nateglinide 120 mg three times daily	Chinese type 2 diabetes mellitus patients	Parallel groups double-blind

continued...

Trial	Treatments	Patients	Trials design and methods
mitiglinide vs on top insulin glargine			
Kumashiro , 2007 n=NA follow-up:	mitiglinide versus on top of once daily insulin glargine	-	
repaglinide vs on top pioglitazone			
Raskin , 2001 n=NA	-	-	
repaglinide vs on top rosiglitazone			
Raskin , 2001 n=NA	-	-	
repaglinide vs on top troglitazone			
Raskin , 2000 n=256 follow-up: 22 weeks	repaglinide (0.54.0 mg at meals), versus combination of repaglinide (14 mg at meals) and troglitazone (200600 mg once daily)	Patients with type 2 diabetes who had inadequate glycemic control (HbA1c 7.0%) during previous monotherapy	open
nateglinide vs placebo			
CDJN608AUS13 n=NA	-	-	
CDJN608AUS13 n=NA	-	-	
CDJN608A ES03 <i>unpublished</i> n=NA follow-up:	-	-	
NAVIGATOR n=NA follow-up:	-	patients with impaired glucose toler-ance (IGT)	
Schwarz , 2008 n=66 follow-up: 12 weeks	nateglinide monotherapy (120 mg, before meals) versus placebo	drug-naive patients with T2DM aged >or=65 years	double-blind
Schwarz (study 2) , 2008 n=NA follow-up: 12 weeks	nateglinide monotherapy (120 mg, before meals) versus	drug-naive patients with T2DM aged >or=65 years	double-blind
Hanefeld , 1990 n=229/60 follow-up: 12 weeks	nateglinide at doses of 30 mg, 60 mg, 120 mg, or 180 mg versus placebo	-	Parallel groups double-blind
Horton , 2000 n=179/172 follow-up:	120 mg nateglinide before meals versus placebo	patients with an HbA1c level between 6.8 and 11.0% during a 4-week placebo run-in	Parallel groups double-blind
Mari , 2005 n=108 follow-up: 24 weeks	30, 60, or 120 mg nateglinide versus placebo	mild type 2 diabetic men and women (fasting glucose 7.0-8.3 mmol/l) on diet treatment	Parallel groups double-blind

continued...

Trial	Treatments	Patients	Trials design and methods
Marre , 2002 n=NA follow-up:	nateglinide 60 mg, 120 mg before three meals versus placebo	metformin-treated patients with HbA1c between 6.8% and 11%	Parallel groups double-blind
Moses , 2001 n=408 follow-up: 16 weeks	0.5 mg repaglinide at mealtimes (increased to 1 mg after 4 weeks depending on blood glucose response) versus placebo	patients with type 2 diabetes considered poorly controlled by diet, but without a history of previous antidiabetic medication	Parallel groups double-blind
Saloranta , 2002 n=675 follow-up: 24 weeks	nateglinide (30, 60, or 120 mg, with meals). versus placebo	patients with type 2 diabetes but only moderately elevated fasting plasma glucose (FPG = 7.0-8.3 mmol/liter)	Parallel groups double-blind
repaglinide vs placebo			
Goldberg , 1998 n=66/33 follow-up: 18 weeks	repaglinide versus placebo	patients with type 2 diabetes	Parallel groups double-blind
Jovanovic , 2000 n=286/75 follow-up: 24 weeks	repaglinide 1 mg (n = 140), or repaglinide 4 mg (n = 146) versus placebo	-	double-blind
Chuang , 1999 n=NA	-	-	
Bech , 2003 n=253 follow-up: 16 weeks	repaglinide initiated at 0.5 mg per meal, increased to 1 mg after 4 weeks if fasting plasma glucose exceeded 7.8 mmol/l. versus placebo	pharmacotherapy-naive patients with Type 2 diabetes	Parallel groups double-blind
Goldberg , 1998 n=66/33 follow-up:	repaglinide versus placebo	type 2 diabetes	Parallel groups double-blind
Jovanovic , 2000 n=286/75 follow-up: 24 weeks	repaglinide 1 mg or repaglinide 4 mg versus placebo	-	Parallel groups double-blind
nateglinide vs placebo (add on insulin)			
Dashora , 2007 n=55 follow-up: 16 weeks	nateglinide before meals versus placebo	-	double-blind
nateglinide vs placebo (add on insulin+MET)			
Juurinen , 2009 n=NA follow-up: 24 weeks	nateglinide (120 mg three times daily) before main meals versus placebo (add on insulin+MET)	Type 2 diabetes treated with the combination of basal insulin and metformin	Parallel groups double-blind
mitiglinide vs placebo (add on MET)			

continued...

Trial	Treatments	Patients	Trials design and methods
NCT01037842 [NCT01037842] n=NA follow-up: 16 weeks	mitiglinide versus placebo	patients with type 2 diabetes who show inadequate glycemic control with metformin monotherapy	double-blind Korea
EX-1510-CT-003 [NCT00519142] n=NA follow-up: 24 weeks	metformin + mitiglinide three times a day with meals versus (metformin + placebo for mitiglinide)	patients with Type 2 diabetes mellitus not well controlled with metformin alone	double-blind US
nateglinide vs placebo (add on standard treatment)			
NCT00402909 [NCT00402909] n=NA follow-up:	-	patients with type 2 diabetes who are not achieving glycemic control with glargine, metformin and/or thiazolidinedione only	double-blind
nateglinide vs placebo (add on TZD)			
026-CL-004 <i>ongoing</i> [NCT00189774] n=NA follow-up:	nateglinide versus placebo (on top pioglitazone)	inadequately controlled type 2 diabetic patients with pioglitazone treatment	double-blind Japan
repaglinide vs placebo (on top bedtime NPH-insulin)			
Landin-Olsson , 1999 n=NA	-	-	
mitiglinide vs placebo (on top pioglitazone)			
Kaku , 2009 n=NA follow-up: 16 weeks	additional mitiglinide 5 or 10 mg tid versus placebo on top pioglitazone	Japanese type 2 diabetic patients who are insufficiently controlled by pioglitazone monotherapy	Parallel groups multicenter
metformin + repaglinide vs repaglinide			
AGEE-1411 [NCT01465152] n=NA follow-up: 24 weeks	metformin and repaglinide versus repaglinide	subjects with type 2 diabetes in which diet and exercise have failed	open Spain
nateglinide vs repaglinide			
Rosenstock , 2004 n=74/76 follow-up: 16 week	nateglinide monotherapy versus repaglinide monotherapy	type 2 diabetic patients previously treated with diet and exercise	open
Li , 2009 n=NA follow-up:	Nateglinide versus repaglinide	-	
Li , 2007 n=115/115 follow-up: 12 weeks	nateglinide 90 mg three times daily versus repaglinide 1.0 mg three times daily	Chinese patients with type 2 diabetes	Parallel groups
repaglinide + metformin vs repaglinide			

continued...

Trial	Treatments	Patients	Trials design and methods
AGEE-3705 [NCT00819741] n=NA follow-up:	repaglinide plus metformin versus repaglinide alone	Chinese subjects with type 2 diabetes having an HbA1c (glycosylated haemoglobin A1c) over 8.5 % and who never have taken oral sugar-lowering drugs before	open China
AGEE-3018 n=NA follow-up:	-	-	
repaglinide + metformin vs rosiglitazone + metformin			
Raskin , 2009 [NCT00399711] n=NA follow-up: 26 weeks	repaglinide and metformin fixed dose combination tablet given as twice daily versus twice daily rosiglitazone and metformin fixed dose combination	subjects with type 2 diabetes currently on monotherapy	open USA
repaglinide + metformin vs SU or MET			
AGEE-3017 [NCT00568984] n=NA follow-up:	combination therapy of repaglinide and metformin versus conventional treatment with a sulphonylurea or metformin in monotherapy	-	China
nateglinide vs gliclazide (add on MET)			
Ristic , 2006 n=133/129 follow-up: 24 weeks	nateglinide plus metformin versus gliclazide plus metformin	Patients with inadequate glucose control on maximal doses of metformin	Parallel groups double-blind

References

YSRE0001, 0:

Moses, 1999:

Moses R, Slobodniuk R, Boyages S, Colagiuri S, Kidson W, Carter J, Donnelly T, Moffitt P, Hopkins H Effect of repaglinide addition to metformin monotherapy on glycemic control in patients with type 2 diabetes. *Diabetes Care* 1999;22:119-24 [[10333912](#)]

Moses R Repaglinide in combination therapy with metformin in Type 2 diabetes. *Exp Clin Endocrinol Diabetes* 1999;107 Suppl 4:S136-9 [[10522839](#)] [10.1055/s-0029-1212169](#)

Landgraf, 1999:

Landgraf R, Bilo HJ, Mller PG A comparison of repaglinide and glibenclamide in the treatment of type 2 diabetic patients previously treated with sulphonylureas. *Eur J Clin Pharmacol* 1999;55:165-71 [[10379630](#)]

Marbury, 1999:

Marbury T, Huang WC, Strange P, Lebovitz H Repaglinide versus glyburide: a one-year comparison trial. *Diabetes Res Clin Pract* 1999;43:155-66 [[10369424](#)]

Wolffenbuttel, 1999:

Wolffenbuttel BH, Landgraf R A 1-year multicenter randomized double-blind comparison of repaglinide and glyburide for the treatment of type 2 diabetes. Dutch and German Repaglinide Study Group. *Diabetes Care* 1999;22:463-7 [[10097930](#)]

Derosa , 2009:

Derosa G, D'Angelo A, Fogari E, Salvadeo S, Gravina A, Ferrari I, Cicero AF Nateglinide and glibenclamide metabolic effects in nave type 2 diabetic patients treated with metformin. *J Clin Pharm Ther* 2009;34:13-23 [[19125899](#)] [10.1111/j.1365-2710.2008.00984.x](#)

Derosa G, D'Angelo A, Fogari E, Salvadeo S, Gravina A, Ferrari I, Cicero AF Effects of nateglinide and glibenclamide on prothrombotic factors in nave type 2 diabetic patients treated with metformin: a 1-year, double-blind, randomized clinical trial. *Intern Med* 2007;46:1837-46 [[18025765](#)]

AGEE-3783, 0:**Madsbad, 2001:**

Madsbad S, Kilhøvd B, Lager I, Mustajoki P, Dejgaard A Comparison between repaglinide and glipizide in Type 2 diabetes mellitus: a 1-year multicentre study. *Diabet Med* 2001;18:395-401 [[11472451](#)]

PRESERVE-beta, :

Gerich J, Raskin P, Jean-Louis L, Purkayastha D, Baron MA PRESERVE-beta: two-year efficacy and safety of initial combination therapy with nateglinide or glyburide plus metformin. *Diabetes Care* 2005;28:2093-9 [[16123472](#)]

AGEE-1524, 0:**AGEE-3020, :****GLORIA, 0:****Horton DOUBLON, 2000:**

Horton ES, Foley JE, Shen SG, Baron MA Efficacy and tolerability of initial combination therapy with nateglinide and metformin in treatment-naïve patients with type 2 diabetes. *Curr Med Res Opin* 2004;20:883-9 [[15200747](#)] [10.1185/030079903125003881](#)

Horton ES, Clinkingbeard C, Gatlin M, Foley J, Mallows S, Shen S Nateglinide alone and in combination with metformin improves glycaemic control by reducing mealtime glucose levels in type 2 diabetes. *Diabetes Care* 2000;23:1660-5 [[11092289](#)]

ReMet, 0:**Lund, 2007:**

Lund SS, Tarnow L, Stehouwer CD, Schalkwijk CG, Frandsen M, Smidt UM, Pedersen O, Parving HH, Vaag A Targeting hyperglycaemia with either metformin or repaglinide in non-obese patients with type 2 diabetes: results from a randomized crossover trial. *Diabetes Obes Metab* 2007 May;9:394-407 [[17391168](#)]

AGEE-1411, :**Reform, 0:**

Lund SS, Tarnow L, Frandsen M, Nielsen BB, Hansen BV, Pedersen O, Parving HH, Vaag AA Combining insulin with metformin or an insulin secretagogue in non-obese patients with type 2 diabetes: 12 month, randomised, double blind trial. *BMJ* 2009;339:b4324 [[19900993](#)]

Gao, 0:

Gao X, , Multicentre, double-blind, randomized study of mitiglinide compared with nateglinide in type 2 diabetes mellitus patients in China. *J Int Med Res* ;37:812-21. [[19589264](#)]

Kumashiro, 2007:

Kumashiro N, Yoshihara T, Kanazawa Y, Shimizu T, Watada H, Tanaka Y, Fujitani Y, Kawamori R, Hirose T, Long-term effect of combination therapy with mitiglinide and once daily insulin glargine in patients who were successfully switched from intensive insulin therapy in short-term study. *Endocr J* 2007;54:163-6. [[17185877](#)]

Raskin, 2001:

Jovanovic L, Jain R, Greco S, et al. Repaglinide/pioglitazone combination therapy of type 2 diabetes *Diabetes* 2001; 50 Suppl. 2: A439

Raskin, 2001:

Raskin P, McGill J, Hale P, et al. Repaglinide/rosiglitazone combination therapy of type 2 diabetes *Diabetes* 2001; 50 Suppl. 2: A128

Raskin, 2000:

Raskin P, Jovanovic L, Berger S, Schwartz S, Woo V, Ratner R Repaglinide/troglitazone combination therapy: improved glycaemic control in type 2 diabetes. *Diabetes Care* 2000;23:979-83 [[10895850](#)]

CDJN608AUS13 , :**CDJN608AUS13 , :****CDJN608A ES03, :****NAVIGATOR, :**

Holman RR, Haffner SM, McMurray JJ, Bethel MA, Holzhauer B, Hua TA, Belenkov Y, Boolell M, Buse JB, Buckley BM, Chacra AR, Chiang FT, Charbonnel B, Chow CC, Davies MJ, Deedwania P, Diem P, Einhorn D, Fonseca V, Fulcher GR, Gaciong Z, Gaztambide S, Giles T Effect of nateglinide on the incidence of diabetes and cardiovascular events. *N Engl J Med* 2010 Apr 22;362:1463-76 [20228402] [10.1056/NEJMoa1001122](#)

Califf RM, Boolell M, Haffner SM, Bethel MA, McMurray J, Duggal A, Holman RR Prevention of diabetes and cardiovascular disease in patients with impaired glucose tolerance: rationale and design of the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial. *Am Heart J* 2008;156:623-32 [18946890]

Schwarz , 2008:

Schwarz SL, Gerich JE, Marcellari A, Jean-Louis L, Purkayastha D, Baron MA Nateglinide, alone or in combination with metformin, is effective and well tolerated in treatment-naive elderly patients with type 2 diabetes. *Diabetes Obes Metab* 2008;10:652-60 [17941876] [10.1111/j.1463-1326.2007.00792.x](#)

Schwarz (study 2), 2008:

Schwarz SL, Gerich JE, Marcellari A, Jean-Louis L, Purkayastha D, Baron MA Nateglinide, alone or in combination with metformin, is effective and well tolerated in treatment-naive elderly patients with type 2 diabetes. *Diabetes Obes Metab* 2008;10:652-60 [17941876] [10.1111/j.1463-1326.2007.00792.x](#)

Hanefeld, 1990:

Hanefeld M, Bouter KP, Dickinson S, Guitard C Rapid and short-acting mealtime insulin secretion with nateglinide controls both prandial and mean glycemia. *Diabetes Care* 2000;23:202-7 [10868832]

Horton, 2000:

Horton ES, Clinkingbeard C, Gatlin M, Foley J, Mallows S, Shen S Nateglinide alone and in combination with metformin improves glycaemic control by reducing mealtime glucose levels in type 2 diabetes. *Diabetes Care* 2000;23:1660-5 [11092289]

Mari, 2005:

Mari A, Gastaldelli A, Foley JE, Pratley RE, Ferrannini E Beta-cell function in mild type 2 diabetic patients: effects of 6-month glucose lowering with nateglinide. *Diabetes Care* 2005;28:1132-8 [15855578]

Marre, 2002:

Marre M, Van Gaal L, Usadel KH, Ball M, Whatmough I, Guitard C Nateglinide improves glycaemic control when added to metformin monotherapy: results of a randomized trial with type 2 diabetes patients. *Diabetes Obes Metab* 2002;4:177-86 [12047396]

Moses, 2001:

Moses RG, Gomis R, Frandsen KB, Schlienger JL, Dedov I Flexible meal-related dosing with repaglinide facilitates glycaemic control in therapy-naive type 2 diabetes. *Diabetes Care* 2001;24:11-5 [11194214]

Saloranta, 2002:

Saloranta C, Hershon K, Ball M, Dickinson S, Holmes D Efficacy and safety of nateglinide in type 2 diabetic patients with modest fasting hyperglycemia. *J Clin Endocrinol Metab* 2002;87:4171-6 [12213867]

Goldberg, 1998:

Goldberg RB, Einhorn D, Lucas CP, Rendell MS, Damsbo P, Huang WC, Strange P, Brodows RG A randomized placebo-controlled trial of repaglinide in the treatment of type 2 diabetes. *Diabetes Care* 1998;21:1897-903 [9802740]

Jovanovic, 2000:

Jovanovic L, Dailey G 3rd, Huang WC, Strange P, Goldstein BJ Repaglinide in type 2 diabetes: a 24-week, fixed-dose efficacy and safety study. *J Clin Pharmacol* 2000;40:49-57 [10631622]

Chuang, 1999:

Chuang LM, Tai TY, Juang JH, et al. Effect of a prandial glucose regulator (NovoNorm) at two doses (0.5mg and 2.0mg) on glycaemic control in type 2 diabetes in Taiwan *JAMA SE Asia* 1999; 51 (1): 22-5

Bech, 2003:

Bech P, Moses R, Gomis R The effect of prandial glucose regulation with repaglinide on treatment satisfaction, wellbeing and health status in patients with pharmacotherapy naive Type 2 diabetes: a placebo-controlled, multicentre study. *Qual Life Res* 2003;12:413-25 [12797714]

Goldberg, 1998:

Goldberg RB, Einhorn D, Lucas CP, Rendell MS, Damsbo P, Huang WC, Strange P, Brodows RG A randomized placebo-controlled trial of repaglinide in the treatment of type 2 diabetes. *Diabetes Care* 1998;21:1897-903 [[9802740](#)]

Jovanovic, 2000:

Jovanovic L, Dailey G 3rd, Huang WC, Strange P, Goldstein BJ Repaglinide in type 2 diabetes: a 24-week, fixed-dose efficacy and safety study. *J Clin Pharmacol* 2000;40:49-57 [[10631622](#)]

Dashora , 2007:

Dashora UK, Sibal L, Ashwell SG, Home PD Insulin glargine in combination with nateglinide in people with Type 2 diabetes: a randomized placebo-controlled trial. *Diabet Med* 2007;24:344-9 [[17298589](#)] [10.1111/j.1464-5491.2007.02094.x](#)

Juurinen , 2009:

Juurinen L, Tiikkainen M, Saltevo J, Nikkil K, Lanki H, Leppvuori E, Kock T, Teikari-Myyr T, Kauppinen-Mkelin R, Kotronen A, Yki-Jrvinen H Nateglinide combination therapy with basal insulin and metformin in patients with Type 2 diabetes. *Diabet Med* 2009;26:409-15 [[19388972](#)] [10.1111/j.1464-5491.2009.02691.x](#)

NCT01037842, :**EX-1510-CT-003, 0:****NCT00402909, :****026-CL-004, 0:****Landin-Olsson, 1999:**

Landin-OlssonM, Brogard JMM, Eriksson J, et al. The efficacy of repaglinide administered in combination with bedtime NPH-insulin in patients with type 2 diabetes. A randomized, semi-blinded, parallel-group, multi-centre trial [abstract] *Diabetes* 1999 May; 48 Suppl. 1: A117

Kaku, 2009:

Kaku K, Tanaka S, Origasa H, Kikuchi M, Akanuma Y, Addition of mitiglinide to pioglitazone monotherapy improves overall glycemic control in Japanese patients with type 2 diabetes: a randomized double blind trial. *Endocr J* 2009;56:657-64. [[19352048](#)]

AGEE-1411, 0:**Rosenstock , 2004:**

Rosenstock J, Hassman DR, Madder RD, Brazinsky SA, Farrell J, Khutoryansky N, Hale PM Repaglinide versus nateglinide monotherapy: a randomized, multicenter study. *Diabetes Care* 2004;27:1265-70 [[15161773](#)]

Li, 2009:

Li C, Xia J, Zhang G, Wang S, Wang L Nateglinide versus repaglinide for type 2 diabetes mellitus in China. *Acta Diabetol* 2009 Dec;46:325-33 [[19183841](#)]

Li, 2007:

Li J, Tian H, Li Q, Wang N, Wu T, Liu Y, Ni Z, Yu H, Liang J, Luo R, Li Y, Huang L Improvement of insulin sensitivity and beta-cell function by nateglinide and repaglinide in type 2 diabetic patients - a randomized controlled double-blind and double-dummy multicentre clinical trial. *Diabetes Obes Metab* 2007 Jul;9:558-65 [[17587398](#)]

AGEE-3705, 0:**AGEE-3018, :****Raskin , 2009:**

Raskin P, Lewin A, Reinhardt R, Lyness W Twice-daily dosing of a repaglinide/metformin fixed-dose combination tablet provides glycaemic control comparable to rosiglitazone/metformin tablet. *Diabetes Obes Metab* 2009 Sep;11:865-73 [[19476470](#)] [10.1111/j.1463-1326.2009.01062.x](#)

AGEE-3017, 0:**Ristic, 2006:**

Ristic S, Collober-Maugeais C, Pecher E, Cressier F Comparison of nateglinide and gliclazide in combination with metformin, for treatment of patients with Type 2 diabetes mellitus inadequately controlled on maximum doses of metformin alone. *Diabet Med* 2006;23:757-62 [[16842480](#)] [10.1111/j.1464-5491.2006.01914.x](#)

Ristic S, Collober-Maugeais C, Cressier F, Tang P, Pecher E Nateglinide or gliclazide in combination with metformin for treatment of patients with type 2 diabetes mellitus inadequately controlled on maximum doses of metformin alone: 1-year trial results. *Diabetes Obes Metab* 2007;9:506-11 [17587393] [10.1111/j.1463-1326.2006.00632.x](https://doi.org/10.1111/j.1463-1326.2006.00632.x)

2 About TrialResults-center.org

TrialResults-center is an innovative knowledge database that collects the results of RCTs and provides dynamic interactive systematic reviews and meta-analysis in the field of all major heart and vessels diseases.

The TrialResults-center database provides a unique view of the treatment efficacy based on all data provided directly from clinical trial results, offering a valuable alternative to personal bibliographic search, published meta-analysis, etc. Furthermore, it would allow comparing easily the various concurrent therapeutic for the same clinical condition.

Rigorous meta-analysis method is used to populate TrialResults-center: widespread search of published and non published trials, study selection using pre-specified criteria, data extraction using standard form.

TrialResults-center is continually updated on a weekly basis. We continually search all new results (whatever their publication channel) and these news results are immediately added to the database with a maximum of 1 week.

TrialResults-center is non-profit and self-funded.